AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | n/a |
Market Cap | 7.50M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -24.46 |
PE Ratio (ttm) | -0.06 |
Forward PE | n/a |
Analyst | Buy |
Ask | n/a |
Volume | 2,744 |
Avg. Volume (20D) | 30,314 |
Open | 1.48 |
Previous Close | 1.51 |
Day's Range | 1.29 - 1.60 |
52-Week Range | 0.87 - 10.80 |
Beta | undefined |
About ORGS
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing ...
Analyst Forecast
According to 1 analyst ratings, the average rating for ORGS stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
2 years ago · proactiveinvestors.ca
Orgenesis sees 2Q revenue of $7.2M; eyes future sales from POCare platformOrgenesis (NASDAQ:ORGS) Inc announced second-quarter 2022 revenue of $7.2 million and provided a business update for the period ending June 30, 2022. The global biotech company also said it secured a ...
2 years ago · proactiveinvestors.com
Orgenesis enters second phase of POCare Platform rollout; sees recurring revenues from long-term contracts for the next 2-3 yearsOrgenesis (NASDAQ:ORGS) Inc, the global biotech company working to unlock the full potential of cell and gene therapies, has said it is entering the second phase of its POCare Platform rollout, and ex...
2 years ago · proactiveinvestors.com
Orgenesis says consortium led by its MIDA Biotech subsidiary wins 4 million euro grant supporting cutting edge technologyOrgenesis (NASDAQ:ORGS) Inc said that a consortium led by its subsidiary, MIDA Biotech, has won a 4-million-euro grant under the European Innovation Council Pathfinder Challenge Program which supports...
2 years ago · proactiveinvestors.com
Orgenesis sees revenue and profits soar in 2021 as its Point of Care platform gains traction around the globeOrgenesis (NASDAQ:ORGS) Inc reported a more than four-fold increase in revenue in 2021 from a year earlier, thanks to growing uptake of its Point of Care (POCare) platform. For the 2021 financial year...
2 years ago · proactiveinvestors.com
Orgenesis achieves latest milestone in its collaboration with Hospital Infantil Universitario Niño Jesús in MadridOrgenesis (NASDAQ:ORGS) Inc said it has achieved its latest milestone in the second phase of its collaboration with the Hospital Infantil Universitario Niño Jesús in Madrid, Spain. The milestone has b...
2 years ago · proactiveinvestors.com
Wall Street stumbles amid looming interest rate hike worries12:05pm: US markets trend downward US stocks continued to plummet midday on Tuesday, as investors eyed earnings reports from some major corporates and fretted over looming interest rate rises. At noon...
2 years ago · proactiveinvestors.com
Orgenesis and Johns Hopkins University to create Maryland center for cell therapy manufacturingOrgenesis (NASDAQ:ORGS) Inc announced the next phase of collaboration with Johns Hopkins University, which involves the construction of a cell and gene therapy processing facility for point of care (P...
3 years ago · proactiveinvestors.com
Orgenesis and Theracell JV to receive up to €32M from Greek government to accelerate the rollout of therapiesOrgenesis (NASDAQ:ORGS) Inc announced that its joint venture (JV) with Theracell Advanced Biotechnology SA in Greece has been designated a “Priority Investment of Strategic National Importance.” The...
3 years ago · proactiveinvestors.com
Orgenesis enters collaboration agreement with Tel Aviv Sourasky Medical Center to establish point-of-care cell therapy centerOrgenesis (NASDAQ:ORGS) Inc. said it entered into a collaboration agreement with Tel Aviv Sourasky Medical Center to establish a point-of-care (POCare) cell therapy center at the Ichilov Hospital, a l...
3 years ago · proactiveinvestors.com
Orgenesis reports 425% surge in 3Q revenue as POCare platform gains scaleOrgenesis (NASDAQ:ORGS) Inc announced a more than five-fold increase in third-quarter revenue as it continues to roll out its Point of Care (POCare) platform. The global biotech company, which is foc...
3 years ago · proactiveinvestors.com
Orgenesis leading the charge at an exciting time for cell therapyGlobal biotech unlocking the potential of personalized therapies and closed processing systems helpful in manufacturing Maryland-based firm has a Cell and Gene Therapy (CGT) Biotech platform The platf...
3 years ago · proactiveinvestors.com
Orgenesis strikes collaboration agreement with Savicell Diagnostics to advance its cell and gene therapy platformOrgenesis Inc announced a new collaboration with biotech firm Savicell Diagnostics Ltd to accelerate the development and manufacturing of its cell and gene therapy platform. The wide-ranging agreement...